Your browser doesn't support javascript.
loading
KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations?
de Macedo, Mariana Petaccia; de Lima, Luiz Guilherme Cernaglia Aureliano; Begnami, Maria Dirlei Ferreira de Souza; de Melo, Fernanda Machado; Andrade, Louise D Brot; Lisboa, Bianca Cristina Garcia; Soares, Luisa Martelli; Soares, Fernando Augusto; Carraro, Dirce Maria; da Cunha, Isabela Werneck.
Afiliação
  • de Macedo MP; Department of Molecular Diagnosis, Anatomic Pathology Department, AC Camargo Cancer Center, São Paulo, Brazil. Electronic address: maripetaccia@gmail.com.
  • de Lima LG; Department of Molecular Diagnosis, Anatomic Pathology Department, AC Camargo Cancer Center, São Paulo, Brazil.
  • Begnami MD; Department of Molecular Diagnosis, Anatomic Pathology Department, AC Camargo Cancer Center, São Paulo, Brazil.
  • de Melo FM; Department of Molecular Diagnosis, Anatomic Pathology Department, AC Camargo Cancer Center, São Paulo, Brazil.
  • Andrade LD; Department of Molecular Diagnosis, Anatomic Pathology Department, AC Camargo Cancer Center, São Paulo, Brazil.
  • Lisboa BC; Department of Molecular Diagnosis, Anatomic Pathology Department, AC Camargo Cancer Center, São Paulo, Brazil.
  • Soares LM; Veterinary Medicine School, UNESP, Botucatu, Brazil.
  • Soares FA; Department of Molecular Diagnosis, Anatomic Pathology Department, AC Camargo Cancer Center, São Paulo, Brazil.
  • Carraro DM; Laboratory of Genomics and Molecular Biology, CIPE, Brazil.
  • da Cunha IW; Department of Molecular Diagnosis, Anatomic Pathology Department, AC Camargo Cancer Center, São Paulo, Brazil.
Exp Mol Pathol ; 96(2): 257-60, 2014 Apr.
Article em En | MEDLINE | ID: mdl-24594115
INTRODUCTION: KRAS mutations are negative predictors of the response to anti-EGFR therapy in colorectal carcinomas (CRCs). Point mutations in codons 12, 13, and 61 are the most common KRAS mutations in CRC. There are few reports on insertions in KRAS, and little is known about its ability to activate the RAS pathway. The scarcity of data regarding insertion frequencies and nucleotide additions in KRAS impedes the management of patients with such mutations. We present data on KRAS insertions in CRC and discuss a case. MATERIALS AND METHODS: Pyrosequencing and Sanger sequencing were performed to identify KRAS and BRAF mutations in paraffin-embedded samples of CRC. Expression of mismatch repair proteins was examined by immunohistochemistry. RESULTS: We detected a GGT insertion between codons 12 and 13 (c.36_37insGGT;p.G12_G13insG) in a CRC patient. We found that insertions in KRAS is very rare in CRC and that the most frequent type of insertion is c.36_37insGGT. CONCLUSIONS: KRAS gene insertions represent a diagnostic and clinical challenge due to the difficult and unusual pyrosequencing findings and the lack of information regarding its clinical impact.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Mutagênese Insercional / Proteínas Proto-Oncogênicas / Proteínas ras / Proteínas Proto-Oncogênicas B-raf Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Mutagênese Insercional / Proteínas Proto-Oncogênicas / Proteínas ras / Proteínas Proto-Oncogênicas B-raf Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article